Development and Validation of a Nomogram to Predict the Probability of Breast Cancer Pathologic Complete Response after Neoadjuvant Chemotherapy: A Retrospective Cohort Study

Yijun Li, Jian Zhang, Bin Wang, Huimin Zhang, Jianjun He†* and Ke Wang†*

Department of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Background: The methods used to predict the pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) have some limitations. In this study, we aimed to develop a nomogram to predict breast cancer pCR after NAC based on convenient and economical multi-system hematological indicators and clinical characteristics.

Materials and Methods: Patients diagnosed from July 2017 to July 2019 served as the training group (N = 114), and patients diagnosed in July 2019 to July 2021 served as the validation group (N = 102). A nomogram was developed according to eight indices, including body mass index, platelet distribution width, monocyte count, albumin, cystatin C, phosphorus, hemoglobin, and D-dimer, which were determined by multivariate logistic regression. Internal and external validation curves are used to calibrate the nomogram.

Results: The area under the receiver operating characteristic curve was 0.942 (95% confidence interval 0.892–0.992), and the concordance index indicated that the nomogram had good discrimination. The Hosmer–Lemeshow test and calibration curve showed that the model was well-calibrated.

Conclusion: The nomogram developed in this study can help clinicians accurately predict the possibility of patients achieving the pCR after NAC. This information can be used to decide the most effective treatment strategies for patients.

Keywords: breast cancer, neoadjuvant chemotherapy, nomogram, clinical cancer research, pathologic complete response

INTRODUCTION

Breast cancer is the most common malignant tumor observed in females worldwide (1). Neoadjuvant chemotherapy (NAC) is widely used and has important implications for patients with locally advanced breast cancer. In these patients, NAC can reduce tumor diameter and staging, which increases the possibility of operation or breast-conserving surgery and reduces
the necessity for axillary lymph node dissection. Although it is still controversial whether NAC can provide long-term survival benefits to patients (2–4), the pathological complete response (pCR) can be used as an alternative index of disease-free survival and overall survival (5–7).

The prediction of the pCR before the start of NAC is very important for clinicians to formulate individualized and precise treatment plans for patients. Firstly, for patients with a low possibility of reaching pCR, abandoning NAC and choosing surgery as soon as possible can not only avoid the toxic effects related to chemotherapy, and save medical costs and resources, but also avoid the time delay caused by NAC, resulting in disease progression. Furthermore, the study of predictors of NAC efficacy will bring new directions for the molecular mechanism of tumorigenesis and chemosensitivity.

Nomograms are widely used to quantify risk in various diseases using intuitive charts combined with known prognostic factors (8). At present, there are some nomograms models for the prediction of pCR in China’s breast cancer population. The methods used to predict pCR include clinicopathological features (9, 10), molecular biomarker analysis (11), medical imaging (12) et al. However, the prediction accuracy of traditional clinicopathological indexes is not satisfactory, while genetic and imaging indexes are expensive, complicated, and have limited application in clinical practice. In recent years, scientists have tried to use common hematological indicators to predict the pCR (13, 14). For example, carbohydrate antigen 153 was proven to be a reliable independent predictor of the pCR (15). Hematological indicators are convenient and economical, but the prediction efficiency of a single indicator is low, and few studies have comprehensively evaluated the combined predictive value of various hematological indicators for the pCR.

In this study, we collected multi-system hematological and clinical characteristics before NAC, and analyzed the relationship between these indicators and NAC efficacy. Finally, we developed a nomogram to predict the possibility of achieving pCR in breast cancer patients.

MATERIALS AND METHODS

Patients and Data Collection

Patients with breast cancer who underwent NAC and surgical treatment at the First Affiliated Hospital of Xi’an Jiaotong University from July 2017 to July 2021 were retrospectively enrolled. Neoadjuvant chemotherapy drugs are based on taxol and/or anthracyclines. Targeted therapeutic drugs were added for all HER2-positive patients. Formulation of the treatment schedule for all patients was determined in accordance with the 2019 version of the National Comprehensive Cancer Network (NCCN) Breast Cancer Clinical Practice Guidelines (16) and discussed by all clinicians in the department.

The inclusion criteria were as follows: (1) invasive breast cancer diagnosed by biopsy; (2) 18–70 years of age; (3) clinical stage II or III breast cancer; (4) fulfillment of the requirements of 2019 NCCN guidelines for NAC for breast cancer (16); (4) completion of all courses of standardized NAC and surgical treatment according to the established scheme. Patients with the following characteristics were excluded: (1) bilateral breast cancer or a second primary cancer; (2) distant metastases identified during treatment; (3) incomplete pathological or hematological examination results; and (4) refusal to participate in the relevant clinical studies. (5) patients with acute diseases (such as acute infection, acute organ dysfunction, etc.) (6) Patients with chronic diseases (such as chronic renal dysfunction, chronic liver dysfunction, chronic coagulopathy, chronic blood system dysfunction, etc.) but not controlled and stable. (7) patients who terminated chemotherapy or changed chemotherapy regimen or cycle due to chronic diseases.

We collected information on patients’ clinical characteristics and hematological indicators from the electronic medical records system. Clinical characteristics included age, clinical stage, clinical tumor stage, clinical lymph node stage, chemotherapy regimen, chemotherapy cycle, menstrual status, molecular typing, estrogen receptor (ER) state, progestrone receptor (PR) state, Ki-67 index, human epidermal growth factor receptor 2 (HER-2) state, and body mass index (BMI). Hematological tests were carried out to assess liver function, renal function, electrolyte concentrations, complete blood counts, and coagulation function. The total number of indicators measured was 61. BMI was calculated by dividing body weight in kilograms by the square of height (m²). Testing for all clinical characteristics and hematological indicators was completed within three days before patients underwent NAC.

The clinical stage was determined by the American Joint Committee on Cancer (17) clinical stage guidelines (8th edition). ER and PR expression of <1% was considered negative by immunohistochemical staining. HER-2 status was determined in accordance with the American Society of Clinical Oncology/College of American Pathologists guidelines (18). Molecular typing was determined by St. Gallen guidelines (19). According to NCCN guidelines [20], pCR was defined as histological evidence that no invasive tumor was found in primary breast lesions or axillary lymph nodes after NAC, regardless of the presence of residual ductal carcinoma in situ (ypT0/isypN0).

It is a retrospective study and the study was approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University.

A complete blood count was conducted using the BC-5390 hematology analyzer (Mindray, Shenzhen, China); the coagulation function test was conducted using the CA7000 automatic hemagglutination apparatus (Sysmex, Kobe, Japan); and liver function, renal function, and electrolyte tests were conducted using the VITROS 5600 automatic biochemical immune analyzer (JNJ, New Jersey, USA).

Statistical Analysis

Patients diagnosed from 2017 to 2019 served as the training group, and patients diagnosed from 2019 to 2021 served as
the validation group. Only age was analyzed as a continuous variable, while all other clinical characteristics and hematological indicators were analyzed as categorical variables. Continuous variables other than age were divided into two groups according to the optimal cut-off value, which was obtained by calculating the maximum Youden’s index (sensitivity + specificity − 1) using the receiver operating characteristic (ROC) curve (20). The Chi-squared test or the Fisher’s exact test was used for analysis. All variables demonstrating a p-value of <0.1 in the univariate analysis were entered into the forward stepwise logistic regression (likelihood ratio) to identify independent predictors, and forest plots were drawn based on the results of multivariate logistic regression. According to the results of logistic regression, a nomogram was established. Internal and external validation curves are used to calibrate the nomogram. A Hosmer–Lemeshow test was performed to check the goodness of fit of the model. The ROC curve, area under the curve (AUC), and concordance index (C-index) were used to display the discrimination of the nomogram. IBM SPSS Statistics (version 22.0; IBM Corporation, Armonk, NY, USA) and R software (version 3.6.2; The R Foundation for Statistical Computing, Austria, Vienna) were used to perform statistical analysis. All p values were two-sided and a p-value of <0.05 was considered statistically significant.

RESULTS

Clinical Characteristics of Patients and the pCR After NAC

A total of 114 eligible patients were enrolled in the training group, and 102 patients were in the validation group. The clinical characteristics of patients in training group were shown in Table 1. The average age of training group patients was 47.9 years. Stage II and stage III breast cancer accounted for 76.3% (87/114) and 23.7% (27/114) of all breast cancers, respectively. Of all patients, 72.8% (83/114) were cT2, 69.3% (79/114) were cN1, 85.1% (97/114) underwent ≥6 chemotherapy cycles, and 56.1% (64/114) were premenopausal. As for the molecular subtype, 43.9% (50/114) of cases were HER-2 positive molecular subtype, 50.9% (58/114) were ER negative, 74.6% (85/114) were PR negative, and 76.3% (87/114) had HER2 expression positivity. The optimal cut-off value was 27.5% for the Ki-67 index and 21.281 kg/m² for BMI. Among the clinical characteristics, a lower clinical stage and a lower BMI correlated with a higher pCR rate (p < 0.1). There was no statistical significance between age, cT stage, cN stage, chemotherapy cycle, chemotherapy regimen, menstrual status, molecular subtype, ER state, PR state, Ki-67 index, HER-2 state, and pCR rate. The clinical characteristics of patients in validation group were shown in Supplementary Table S1.

Table 1: Clinical characteristics of 114 patients with breast cancer and their correlation with the pathologic complete response rate after neoadjuvant chemotherapy.

| Factors | Total (%) | pCR (%) | Non-pCR (%) | p value |
|---------|-----------|---------|-------------|---------|
| Age (years, mean ± SD) | 47.9 ± 10.3 | 47.3 ± 10.1 | 48.2 ± 10.5 | 0.558 |
| Clinical stage | | | | 0.098 |
| II | 87 (76.3) | 27 (31.0) | 60 (96.9) | |
| III | 27 (23.7) | 4 (14.8) | 23 (85.2) | |
| Clinical tumor stage | | | | 0.685 |
| cT1 | 15 (13.2) | 4 (26.7) | 11 (73.3) | |
| cT2 | 83 (72.8) | 22 (26.5) | 61 (73.5) | |
| cT3 | 13 (11.4) | 5 (38.5) | 8 (61.5) | |
| cT4 | 3 (2.6) | 0 (0.0) | 3 (100.0) | |
| Clinical nodal stage | | | | 0.498 |
| cN0 | 11 (9.6) | 4 (36.4) | 7 (63.6) | |
| cN1 | 79 (69.3) | 23 (29.1) | 56 (70.9) | |
| cN2 | 19 (16.7) | 4 (21.1) | 15 (78.9) | |
| cN3 | 5 (4.4) | 0 (0.0) | 5 (100.0) | |
| Chemotherapy regimen | | | | 0.717 |
| TAC/AC-T/ TA | 62 (47.7) | 26 (41.9) | 36 (58.1) | |
| TC/TX/TP/AC | 10 (7.7) | 7 (70.0) | 3 (30.0) | |
| AC-TH/ TCbH | 38 (29.2) | 17 (44.7) | 21 (55.3) | |
| TCbHP/ THP/ AC-THP | 20 (15.4) | 8 (40.0) | 12 (60.0) | |
| Chemotherapy cycle | | | | |
| <6 | 17 (14.9) | 3 (17.6) | 14 (82.4) | 0.555 |
| ≥6 | 97 (85.1) | 28 (28.9) | 69 (71.1) | |
| Menopausal status | | | | 0.271 |
| Prenomenopausal | 64 (56.1) | 20 (31.3) | 44 (68.8) | |
| Peri/postmenopausal | 50 (43.9) | 11 (22.0) | 39 (78.0) | |
| Molecular subtype | | | | 0.659 |
| Luminal B (Her2−) | 7 (6.1) | 2 (28.6) | 5 (71.4) | |
| Luminal B (Her2+) | 37 (32.5) | 11 (29.7) | 26 (70.3) | |
| Her2 positive | 50 (43.9) | 11 (22.0) | 39 (78.0) | |
| Triple negative | 20 (17.5) | 7 (35.0) | 13 (65.0) | |
| Estrogen receptor | | | | 0.174 |
| Negative | 58 (50.9) | 19 (32.8) | 39 (67.2) | |
| Positive | 56 (49.1) | 12 (21.4) | 44 (78.6) | |
| Progesterone receptor | | | | 0.362 |
| Negative | 85 (74.6) | 25 (29.4) | 60 (70.6) | |
| Positive | 29 (25.4) | 6 (20.7) | 23 (79.3) | |
| HER-2 | | | | 0.412 |
| Negative | 27 (23.7) | 9 (33.3) | 18 (66.7) | |
| Positive | 87 (76.3) | 22 (25.3) | 65 (74.7) | |
| Ki-67, % | | | | 0.108 |
| <27.5 | 14 (12.3) | 1 (7.1) | 13 (92.9) | |
| ≥27.5 | 100 (87.7) | 30 (30.0) | 70 (70.0) | |
| Body mass index, kg/m² | | | | 0.073 |
| <21.281 | 24 (21.1) | 10 (41.7) | 14 (58.3) | |
| ≥21.281 | 90 (78.9) | 21 (23.3) | 69 (76.7) | |

NAC, Neoadjuvant chemotherapy; pCR, Pathologic complete response; HER2, Human epidermal growth factor receptor 2. Bold values mean p < 0.1.
| Factors                      | Total (%) | pCR (%) | Non-pCR (%) | P value |
|-----------------------------|-----------|---------|-------------|---------|
| **Liver function test**     |           |         |             |         |
| Alkaline phosphatase, U/L   |           |         |             | 0.083   |
| < 61.5                      | 32 (28.1) | 5 (15.6)| 27 (84.4)   |         |
| ≥ 61.5                      | 82 (79.9) | 26 (31.7)| 56 (68.3)  |         |
| Total protein, g/L          |           |         |             | 0.073   |
| < 79.45                     | 90 (78.9) | 21 (23.3)| 69 (76.7)  |         |
| ≥ 79.45                     | 24 (21.1) | 10 (41.7)| 14 (58.3)  |         |
| Albumin, g/L                |           |         |             | 0.031   |
| < 47.45                     | 83 (72.8) | 18 (21.7)| 65 (78.3)  |         |
| ≥ 47.45                     | 31 (27.2) | 13 (41.9)| 18 (58.1)  |         |
| Creatinine, μmol/L          |           |         |             | 0.069   |
| < 43.5                      | 24 (21.2) | 3 (12.5)| 21 (87.5)  |         |
| ≥ 43.5                      | 90 (78.9) | 28 (31.1)| 62 (68.9)  |         |
| Cystatin C, mg/L            |           |         |             | <0.001  |
| < 1.05                      | 104 (91.2)| 23 (22.1)| 81 (77.9)  |         |
| ≥ 1.05                      | 10 (8.8)  | 8 (80.0)| 2 (20.0)   |         |
| **Electrolyte test**        |           |         |             | 0.704   |
| Potassium, mmol/L           |           |         |             |         |
| < 4.34                      | 95 (83.3) | 29 (30.5)| 66 (69.5)  |         |
| ≥ 4.34                      | 19 (16.7) | 2 (10.5)| 17 (89.5)  |         |
| Phosphorus, mmol/L          |           |         |             | 0.010   |
| < 1.135                     | 66 (57.9) | 24 (36.4)| 42 (63.6)  |         |
| ≥ 1.135                     | 48 (42.1) | 7 (14.6)| 41 (85.4)  |         |
| Calcium, mmol/L             |           |         |             | 0.030   |
| < 2.325                     | 63 (55.3) | 12 (19.0)| 51 (81.0)  |         |
| ≥ 2.325                     | 51 (44.7) | 19 (37.3)| 32 (62.7)  |         |
| **Complete blood count**    |           |         |             | 0.046   |
| Red blood cell count/L      |           |         |             |         |
| < 5.04                      | 108 (94.7)| 27 (25.0)| 81 (75.0)  |         |
| ≥ 5.04                      | 6 (5.3)   | 4 (66.7)| 2 (33.3)   |         |
| Hemoglobin, g/L             |           |         |             | 0.067   |
| < 147.5                     | 103 (90.4)| 25 (24.3)| 78 (75.7)  |         |
| ≥ 147.5                     | 11 (9.6)  | 6 (54.5)| 5 (45.5)   |         |
| Mean corpuscular hemoglobin concentration, g/L | 0.065 |         |             |         |
| < 323.5                     | 99 (86.8) | 30 (30.3)| 69 (69.7)  |         |
| ≥ 323.5                     | 15 (13.2) | 1 (6.7)| 14 (93.3)  |         |
| Platelet distribution width, fL |         |         |             | 0.028   |
| < 14.85                     | 58 (50.9) | 21 (36.2)| 37 (63.8)  |         |
| ≥ 14.85                     | 56 (49.1) | 10 (17.9)| 46 (82.1)  |         |
| Mean platelet volume, fL    |           |         |             | 0.051   |
| < 10.7                      | 34 (29.8) | 5 (14.7)| 29 (85.3)  |         |
| ≥ 10.7                      | 80 (70.2) | 26 (32.5)| 54 (67.5)  |         |
| Platelet large cell ratio, %|           |         |             | 0.068   |
| < 31.5                      | 37 (32.5) | 6 (16.2)| 31 (83.8)  |         |
| ≥ 31.5                      | 77 (67.5) | 25 (32.5)| 52 (67.5)  |         |

(continued)
Correlation Between Hematological Indicators and pCR

The correlation between pCR and 61 hematological indicators was analyzed (Supplementary Table S2). Twenty-three indicators correlated with the pCR rate ($p < 0.1$). The pCR was more likely to be achieved in patients who had high values for alkaline phosphatase (ALP), albumin (ALB), total protein (TP), creatinine (CRE), cystatin C (Cys-C), calcium ($Ca^{2+}$), hemoglobin (HGB), red blood cell (RBC) count, mean platelet volume (MPV), fibrinogen content (FIB), platelet large cell ratio (P-LCR), activated partial thromboplastin time (APTT), and D-dimer (D-D). Conversely, potassium ($K^+$), phosphorus (POH), mean corpuscular hemoglobin concentration (MCHC), platelet distribution width (PDW), monocyte count (MONO), monocyte percentage (MONO%), thrombin time (TT), and thrombin time ratio (TT R) were negatively correlated with pCR (Table 2).

Logistic Regression Analysis of Clinical Characteristics, Hematological Indicators, and pCR

The clinical characteristics and hematological indicators with a $p$-value of $<0.1$ in the Chi-squared test, Mann–Whitney U test, or Fisher’s exact test were included in the logistic regression analysis. Univariate logistic analyses showed similar results, in which patients with low values for clinical stage, BMI, $K^+$, POH, MCHC, PDW, MONO, MONO%, TT, and TT R; and high ALP, TP, ALB, CRE, Cys-C, $Ca^{2+}$, RBC, HGB, MPV, P-LCR, APTT, FIB, and D-D had a higher pCR rate (Table 3). Moreover, multivariate logistic regression showed that BMI, ALB, Cys-C, POH, HGB, PDW, MONO, and D-D were independent predictors for pCR (Table 3). Of these factors, ALB, Cys-C, HGB, and D-D were positively correlated with the pCR rate, while BMI, Cys-C, POH, PDW, and MONO were negatively correlated with the pCR rate (Figure 1).

Development and Validation of the Multi-Factor-Based Nomogram Prediction Model

A nomogram was developed to predict the breast cancer pCR rate after NAC, according to BMI, ALB, Cys-C, POH, HGB, PDW, MONO, and D-D (Figure 2). The predicted pCR rate was calculated by summing the scores of these eight factors. The $p$-value obtained from the Hosmer–Lemeshow test was 0.963, which indicated that the nomogram had a good statistical fit. The internal validation curve (Figure 3) and external validation curve (Figure 4) showed a trend that the true value and the predicted value were consistent. And the C-index of external validation was 0.831 (95% confidence interval 0.815–0.858),...
**TABLE 3** | Logistic regression analysis of clinical characteristics and hematological indicators related to the pathologic complete response rate after neoadjuvant chemotherapy in 114 patients with breast cancer.

| Factors                        | Univariate analysis | Multivariate analysis |
|--------------------------------|---------------------|-----------------------|
|                                | OR  | 95% CI | p value | OR  | 95% CI | p value |
| **Clinical stage**             |     |        |         |     |        |         |
| II                             | 1   |        |         |     |        |         |
| III                            | 0.386 | 0.122–1.226 | 0.107 |     |        |         |
| **Body mass index, kg/m²**     |     |        |         |     |        |         |
| <21.281                        | 1   |        |         |     |        |         |
| ≥21.281                        | 0.426 | 0.165–1.099 | 0.078 | 0.103 | 0.018–0.596 | 0.011 |
| **Liver function test**        |     |        |         |     |        |         |
| Alkaline phosphatase, U/L      |     |        |         |     |        |         |
| <61.5                          | 1   |        |         |     |        |         |
| ≥61.5                          | 2.507 | 0.867–7.248 | 0.090 |     |        |         |
| Total protein, g/L             |     |        |         |     |        |         |
| <79.45                         | 1   |        |         |     |        |         |
| ≥79.45                         | 2.347 | 0.901–6.051 | 0.078 |     |        |         |
| Albumin, g/L                   |     |        |         |     |        |         |
| <47.45                         | 1   |        |         |     |        |         |
| ≥47.45                         | 2.608 | 1.077–6.313 | 0.034 | 9.672 | 1.786–52.375 | 0.008 |
| Creatinine, μmol/L             |     |        |         |     |        |         |
| <43.5                          | 1   |        |         |     |        |         |
| ≥43.5                          | 3.161 | 0.871–11.477 | 0.080 |     |        |         |
| Cystatin C, mg/L               |     |        |         |     |        |         |
| <1.05                          | 1   |        |         |     |        |         |
| ≥1.05                          | 14.087 | 2.796–70.984 | 0.001 | 141.718 | 8.593–2339.925 | 0.001 |
| **Electrolyte test**           |     |        |         |     |        |         |
| Potassium, mmol/L              |     |        |         |     |        |         |
| <4.34                          | 1   |        |         |     |        |         |
| ≥4.34                          | 0.268 | 0.058–1.235 | 0.091 |     |        |         |
| Phosphorus, mmol/L             |     |        |         |     |        |         |
| <1.135                         | 1   |        |         |     |        |         |
| ≥1.135                         | 0.299 | 0.116–0.769 | 0.012 | 0.165 | 0.038–0.706 | 0.015 |
| Calcium, mmol/L                |     |        |         |     |        |         |
| <2.325                         | 1   |        |         |     |        |         |
| ≥2.325                         | 2.523 | 1.082–5.887 | 0.032 |     |        |         |
| **Complete blood count**       |     |        |         |     |        |         |
| Red blood cell count/L         |     |        |         |     |        |         |
| <5.04                          | 1   |        |         |     |        |         |
| ≥5.04                          | 6.000 | 1.040–34.609 | 0.045 |     |        |         |
| Hemoglobin, g/L                |     |        |         |     |        |         |
| <147.5                         | 1   |        |         |     |        |         |
| ≥147.5                         | 3.744 | 1.052–13.324 | 0.042 | 15.022 | 1.101–204.973 | 0.042 |
| Mean corpuscular hemoglobin concentration, g/L |     |        |         |     |        |         |
| <323.5                         | 1   |        |         |     |        |         |
| ≥323.5                         | 0.164 | 0.021–1.307 | 0.088 |     |        |         |
| Platelet distribution width, fl |     |        |         |     |        |         |
| <14.85                         | 1   |        |         |     |        |         |
| ≥14.85                         | 0.383 | 0.161–0.913 | 0.030 | 0.060 | 0.010–0.381 | 0.003 |

*(continued)*
which proving that the nomogram was well-calibrated. In the ROC curve analysis, the AUC of the nomogram was 0.942 (95% confidence interval 0.892–0.992, Figure 5). When the prediction probability of pCR is 33.9%, the model has the optimal cut-off value, with a sensitivity of 83.9%, a specificity of 91.6%, and a C-index of 0.942, all of which proved that the nomogram had good discriminative and predictive abilities.

TABLE 3 | Continued

| Factors                                | Univariate analysis | Multivariate analysis |
|----------------------------------------|---------------------|----------------------|
|                                        | OR                  | 95% CI               | p value |
|                                        | OR                  | 95% CI               | p value |
| Mean platelet volume, fL               |                     |                      |         |
| <10.7                                  | 1                   |                      |         |
| ≥10.7                                  | 2.793               | 0.969–8.045          | 0.057   |
| Platelet large cell ratio, %           |                     |                      |         |
| <31.5                                  | 1                   |                      |         |
| ≥31.5                                  | 2.484               | 0.918–6.724          | 0.073   |
| Monocyte count, 10^9/L                 |                     |                      |         |
| <0.185                                 | 1                   |                      |         |
| ≥0.185                                 | 0.190               | 0.061–0.593          | 0.048   |
| Monocyte percentage,%                  |                     |                      |         |
| <3.55                                  | 1                   |                      |         |
| ≥3.55                                  | 0.321               | 0.120–0.859          | 0.024   |
| Coagulation function test              |                     |                      |         |
| Activated partial thromboplastin time, s|                     |                      |         |
| <35.95                                 | 1                   |                      |         |
| ≥35.95                                 | 2.067               | 0.890–4.803          | 0.091   |
| Thrombin time, S                       |                     |                      |         |
| <16.75                                 | 1                   |                      |         |
| ≥16.75                                 | 0.277               | 0.097–0.794          | 0.017   |
| Thrombin time ratio                    |                     |                      |         |
| <0.985                                 | 1                   |                      |         |
| ≥0.985                                 | 0.277               | 0.097–0.794          | 0.017   |
| Fibrinogen content, g/L                |                     |                      |         |
| <3.085                                 | 1                   |                      |         |
| ≥3.085                                 | 2.656               | 1.137–6.025          | 0.024   |
| D-dimer, mg/L                          |                     |                      |         |
| <0.55                                  | 1                   |                      |         |
| ≥0.55                                  | 4.836               | 1.967–11.885         | 0.001   |

OR, Odds ratio; CI, Confidence interval; NAC, Neoadjuvant chemotherapy; pCR, Pathologic complete response.

DISCUSSION

It is well-recognized that the therapeutic response and prognosis of tumors are not only related to the histopathological characteristics of the tumor itself, but also the state of the host (16). In this study, we analyzed the correlation between several clinical characteristics, hematological indicators, and the pCR. The hematological indicators included a total of 61 clinical laboratory indicators, and covered almost all of the hematological markers commonly measured in the clinic. Notably, these indicators not only showed the clinicopathological features of tumors, but reflected the multi-system function of patients at initial diagnosis. The nomogram was established according to eight independent predictors, namely BMI, ALB, Cys-C, POH, HGB, PDW, MONO, and D-D. The AUC of the ROC curve and the C-index indicated that the nomogram had good discriminative ability, while the Hosmer–Lemeshow test and the calibration curve proved that the nomogram was well-calibrated. These results confirm that our nomogram exhibits a high predictive value. As far as we know, this was the first...
attempt to predict NAC after the pCR in patients with breast cancer through comprehensively analyzing the clinical characteristics and hematological indicators that reflect the function of multiple human systems.

For breast cancer patients in China, one study found that ER, PR, HER2 and primary tumor response were associated with axillary pCR. The C index of the model training group and validation group were 0.834 and 0.756 respectively (10). Guo
et al. confirmed that menopausal status, family history, initial tumor size, ER, HER2 status and Ki-67 were associated with pCR. The AUC value of this model is 0.762 (9). The reasons for different predictors may be related to population selection and different pCR definitions, namely breast pCR and axillary pCR. Among laboratory indicators related to pCR in China’s breast cancer patients, Chen et al showed that the ratio of neutrophils to lymphocytes is related to axillary pCR (21). The ratio of lymphocyte to monocyte, fibrinogen level and D-D level have been reported to predict the pCR possibility in...
three negative breast cancer (22). The mechanism between laboratory indexes and NAC efficacy in different subtypes needs further research.

The nutritional status of patients is closely related to the therapeutic responsiveness and prognosis of breast cancer (23). In our study, we found that patients with a lower BMI, a higher ALB concentration, and a higher HGB concentration had a better response to NAC, which proves that obesity, hypoalbuminemia, and anemia are all risk factors for the pCR. The mechanism can be explained by the imbalance in nutritional status, which can stimulate local and circulating proinflammatory cytokines and tumor stem cells, promoting tumor angiogenesis and driving tumor growth, invasion, and metastasis (24).

The formation of nucleotides, membrane phospholipids, and phosphorylation intermediates in cell signaling require the participation of inorganic P. Rapidly proliferating cells, such as tumor cells, also need large amounts of P-rich ribosomes and RNA to synthesize proteins (25, 26). Therefore, it is theoretically believed that an increase in serum P indicates that tumor cells are rapidly dividing and proliferating, which is why patients with a high P concentration have a poor response to NAC treatment.

Cysteine proteinase is an important matrix metalloproteinase that acts on the cell membrane and assists the active invasion and metastasis of tumor cells (27). As one of the potent effective cysteine proteinase inhibitors in the human body, Cys-C limits the malignant behavior of tumors (28), and an increase in Cys-C has been reported in a number of patients with cancer (29–31). Similar conclusions have been reached in our study, which suggests that patients with a higher Cys-C value have a higher possibility of achieving a pCR.

In our study, patients with a high level of PDW were less likely to achieve a pCR. A high PDW value indicates an increase in the number of immature platelets in the circulatory system, which may be related to the upregulation of interleukin-6, tumor necrosis factor-α, interleukin-1, and other pro-inflammatory cytokines that promote the maturation of heterologous megakaryocytes during tumor development (32).

The activation of innate immunity is a possible mechanism of the correlation between the number of monocytes and the response to chemotherapy and tumor prognosis (33). Monocyte lines increase through upregulation of monocyte chemoattractant protein 1 in tumors (34), and differentiate into tumor-related macrophages, which promote invasion and metastasis of tumor cells by regulating the poor response to NAC. D-D is a degradation product of fibrin induced by plasmin (35). D-D is considered to be a biomarker of hemostasis and fibrinolysis activation and is related to the prognosis of breast cancer (36). Interestingly, contrary to a previous study, we found that patients with a higher D-D concentration were more likely to achieve a pCR. The possible mechanism underpinning this phenomenon is that patients with breast cancer have a hypercoagulable blood state and therefore may be more responsive to NAC.
Inevitably, our study has some limitations that should be highlighted. First, as a retrospective analysis performed at a single center, the number of patients involved was relatively small; thus, it is necessary to conduct external validation in large-scale multicenter research in the future to evaluate our model. Second, factors considered to be related to the pCR in some research, such as tumor stage, molecular typing (37), and Ki-67 index (38), were not confirmed in our study or proven to be independent predictors of the pCR. This may be related to the fact that indicators are not mutually independent or the population selection bias due to single-center study. The specific mechanism needs to be further explored. Third, some of the clinical characteristics of the study population were unbalanced. For example, we had a large proportion of subjects with HER2-positive molecular typing, but no patients with luminal A breast cancer. This bias is possibly because NAC is only suitable for the treatment of certain types of breast cancer. Fourthly, despite our strict exclusion and inclusion criteria, we still cannot avoid the impact of patients’ potential diseases on the results.

CONCLUSION

In conclusion, in this study, we identified eight predictors independently associated with the pCR. We constructed a nomogram model with a prediction accuracy of 0.942. This nomogram can help clinicians easily predict the possibility of patients achieving a pCR after NAC and may aid in the development of effective treatment strategies.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. (2020) 70(1):7–30. doi: 10.3322/caac.21590
2. Early Breast Cancer Trialists’ Collaborative G. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. (2018) 19(1):27–39. doi: 10.1016/S1470-2045(17)30777-5
3. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. (2005) 97(3):188–94. doi: 10.1093/jnci/dj021
4. Smith BL. Neoadjuvant versus adjuvant systemic therapy for operable breast cancer: equivalent outcomes? Ann Surg. (2013) 257(2):180–1. doi: 10.1097/SLA.0b013e318280a688
5. Barker AD, Sigman CC, Kellof GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. (2009) 86(1):97–100. doi: 10.1038/clpt.2009.68
6. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathologic complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. (2014) 384(9938):164–72. doi: 10.1016/S0140-6736(13)62422-8
7. Harrington D, Parmigiani G. I-SPY 2—a glimpse of the future of phase 2 drug development? N Engl J Med. (2016) 375(1):7–9. doi: 10.1056/NEJMep1602256
8. Hoshino N, Hasegawa S, Hida K, Kawada K, Ganeko R, Sugihara K, et al. Nomogram for predicting recurrence in stage II colorectal cancer. Acta Oncol. (2016) 55(12):1414–7. doi: 10.1080/0284186X.2016.1223881
9. Guo R, Su Y, Si J, Xue J, Yang B, Zhang Q, et al. A nomogram for predicting axillary pathologic complete response in hormone receptor-positive breast cancer with cytologically proven axillary lymph node metastases. Cancer. (2020) 126(Suppl 16):3819–29. doi: 10.1002/cncr.32830
10. Hou N, Xiao J, Wang Z, Wu Y, Hou G, Guo L, et al. Development and validation of a nomogram for individually predicting pathologic complete remission after preoperative chemotherapy in Chinese breast cancer: a population-based study. Clin Breast Cancer. (2020) 20(6):e682–94. doi: 10.1016/j.clbc.2020.06.010
11. Li Z, Zhang Y, Zhang Z, Zhao Z, Lv Q. A four-gene signature predicts the efficacy of paclitaxel-based neoadjuvant therapy in human epidermal growth factor receptor 2-negative breast cancer. J Cell Biochem. (2019) 120(4):6046–56. doi: 10.1002/jcb.27891

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

J-JH and KW designed the study. Y-JL, JZ and BW collected the data. H-MZ helped with the statistical analysis. Y-JL wrote the manuscript. JZ, BW, J-JH and KW revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the key research and development project of Shaanxi Province Science and Technology Department (NO. 2020SF-039).

ACKNOWLEDGMENTS

We are thankful to the patients for agreeing to participate in this research. We wish to thank all our colleagues in the Departments of Breast Surgery, First Affiliated Hospital of Xi’an Jiaotong University.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2022.878255/full#supplementary-material.
12. Liu Z, Li Z, Qu J, Zhang R, Zhou X, Li L, et al. Radiomics of multiparametric MRI for pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study. Clin Cancer Res. (2019) 25(12):3538–47. doi: 10.1158/1078-0433.CCR-18-3190

13. Proctor MJ, Talwar D, Bialom SM, O'Reilly C, Follis AK, Horgan PG, et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer. (2010) 103(6):870–6. doi: 10.1038/sj.bjc.6605855

14. Qian Y, Tao J, Li X, Chen H, Lu Q, Yang J, et al. Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy. Oncotargets Ther. (2018) 11:1423–32. doi: 10.2147/OTT.S148496

15. Fujimoto Y, Higuchi T, Nishimaki A, Miyagawa Y, Kira A, Ozawa H, et al. High levels of serum CA15-3 and renalinal invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy. J Surg Oncol. (2018) 118(1):228–37. doi: 10.1002/jso.25215

16. Wang Y, Wang H, Yin W, Lin Y, Zhou L, Sheng X, et al. Novel lymphocyte to red blood cell ratio (LRR), neutrophil to red blood cell ratio (NRR), monocyte to red blood cell ratio (MRR) as predictive and prognostic biomarkers for locally advanced breast cancer. Gland Surg. (2019) 8(6):627–35. doi: 10.21037/gs.2019.10.10

17. Frederick G, David P, Irvin F, April F, Charles B, Daniel H, et al. AJCC cancer staging manual. 8th ed. New York, NY: Springer. (2017).

18. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Defazio A, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/Clinical College of American Pathologists clinical practice guideline update. J Clin Oncol. (2013) 31(3):3997–4013. doi: 10.1200/JCO.2013.50.9984

19. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart MJ, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. (2013) 24(9):2206–23. doi: 10.1093/annonc/mdt303

20. Youden WJ. Index for rating diagnostic tests. Cancer. (1950) 3(1):32–5. doi: 10.1002/1097-0142(195011)3:1<32::aid-cncr2820030106>3.0.co;2-3

21. Chen P, Zhao T, Bi Z, Zhang ZP, Xie L, Liu YB, et al. Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer. Future Oncol. (2021) 17(19):2449–60. doi: 10.2217/fon-2020-1231

22. Zhang F, Huang M, Zhou H, Chen K, Jin J, Wu Y, et al. A nomogram to predict the pathologic complete response of neoadjuvant chemotherapy in triple-negative breast cancer based on simple laboratory indicators. Ann Surg Oncol. (2019) 26(12):3912–9. doi: 10.1245/s10434-019-07655-7

23. De Cicco P, Catani MV, Gasperi V, Siblano M, Quaglietta M, Savini I. Nutrition and breast cancer: a literature review on prevention, treatment and recurrence. Nutrients. (2011) 3(7):1514. doi: 10.3390/nu3071514

24. Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slanger JM. Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin. (2017) 67(5):378–97. doi: 10.3332/caac.21405

25. Kouloulias V, Tolia M, Tsoukalas N, Papaloucas C, Pisteou-Vombaki K, Zygoigliani A, et al. Is there any potential clinical impact of serum phosphorus and magnesium in patients with lung cancer at first diagnosis? A multi-institutional study. Asian Pac J Cancer Prev. (2015) 16(1):77–81. doi: 10.7314/apjcp.2015.16.1.77

26. Low-Beer BV. Surface measurements of radioactive phosphorus in breast tumors as a possible diagnostic method. Science. (1946) 104(2704):399. doi: 10.1126/science.104.2704.399

27. Nishikawa H, Ozaki Y, Nakamishi T, Blomgren K, Tada T, Arakawa A, et al. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol. (2004) 92(3):881–6. doi: 10.1016/j.ygyno.2003.11.017

28. Kos J, Lah T. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Onco Rep. (1998) 5(6):1349–61. doi: 10.3982/or.5.6.1349

29. Teaford HR, Barreto JN, Volinier KJ, Rule AD, Barreto EF. Cystatin C: A Primer for Pharmacists. Pharmacy (Basel). (2020) 8(1):35. doi: 10.3390/pharmacy8010035

30. Leto G, Cresciannino M, Flandina C. On the role of cystatin C in breast cancer progression. Life Sci. (2018) 202:152–60. doi: 10.1016/j.lfs.2018.04.013

31. Marcus B, Arenberg D, Lee J, Kleer C, Chepeha DB, Schmalbach CE, et al. Prognostic factors in oral cavity and oropharyngeal squamous carcinoma. Cancer. (2004) 101(12):2779–87. doi: 10.1002/cncr.20701

32. Batschauer APB, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LMS, Fernandes AP, et al. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. (2010) 21(6):1267–72. doi: 10.1093/annonc/mdp474

33. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. (2012) 97(8):1158–64. doi: 10.3324/haematol.2011.054718

34. Marcus B, Arenberg D, Lee J, Kleer C, Chepeha DB, Schmalbach CE, et al. Prognostic factors in oral cavity and oropharyngeal squamous carcinoma. Cancer. (2004) 101(12):2779–87. doi: 10.1002/cncr.20701

35. Batschauer APB, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LMS, Fernandes AP, et al. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. (2010) 21(6):1267–72. doi: 10.1093/annonc/mdp474

36. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. (2012) 97(8):1158–64. doi: 10.3324/haematol.2011.054718

37. Coto W, Kashiwagi S, Takada K, Asuso Y, Takahashi K, Fujita H, et al. Invasive breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy. J Transl Med. (2018) 16(1):307. doi: 10.1186/s12967-018-1679-0

38. Jain P, Doval DC, Batra U, Goyal P, Bothra SJ, Agarwal C, et al. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer. Jpn J Clin Oncol. (2019) 49(4):329–38. doi: 10.1093/jjco/hyz012

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li, Zhang, Wang, Zhang, He and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.